">
Thursday, 19 March 2026
  
Login

Australia's most trusted
source of pharma news

Thursday, 19 March 2026
News

Novo slapped with Warning Letter

Posted 19 March 2026 PM

The FDA has slapped Novo Nordisk with a Warning Letter for unreported semaglutide safety signals, including deaths, with the TGA “considering the issues raised”.

The warning letter relates to a post-marketing adverse drug experience (PADE) inspection conducted at the Plainsboro, New Jersey site in early 2025, which resulted in a Form FDA 483. The FDA issues documents of this nature after an inspection that outlines improper practice or regulatory shortcomings.

To see the whole article, please login


Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.